Recent Updates
Recently added Catalysts
ANIK Positive Sentiment Score: 70/100

Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference

Key Takeaway: Anika Therapeutics, Inc. announced that Dr. Cheryl Blanchard, President and CEO, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on March 10, 2025. The company will also engage in one-on-one investor meetings during the event. The presentation will be available via a live webcast and will be archived for 30 days on Anika's website. Anika specializes in joint preservation and early intervention orthopedics, highlighting its innovative products in the field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is showcasing leadership by presenting at a prominent conference.
  • Participation in one-on-one investor meetings highlights engagement with stakeholders.
  • Focus on innovative orthopedic solutions demonstrates commitment to advancing healthcare.

Full Press Release Details

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics’ website and will be archived for 30 days following the presentation. For more information about this event or to schedule a one-on-one meeting with Anika’s senior management, please contact Anika’s Investor Relations at investorrelations@anika.com.
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, TACTOSET, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations

Frequently Asked Questions

When will Anika Therapeutics present at the conference?

Anika Therapeutics will present on March 10, 2025, at 2:30 PM PT.

How can I watch Anika's presentation?

The presentation will be webcast live on Anika’s website and archived for 30 days.

What does Anika focus on in its products?

Anika specializes in joint preservation and offers solutions for osteoarthritis pain.

Where is Anika Therapeutics headquartered?

Anika Therapeutics is headquartered near Boston, Massachusetts.

How can I contact Anika's Investor Relations?

You can email investorrelations@anika.com for inquiries related to investments.

Last updated: Feb 25, 2025